&w=3840&q=100)
Bihar economy expected to grow to $1.1 trillion by 2046-47: CII report
In the immediate term, the state's economy is estimated to grow more than double at $219 billion by 2030-31, in an optimistic scenario, industry body CII said in its report.
"CII estimates Bihar's economy to more than double by 2030-31 and reach $219 billion levels (the optimistic scenario). Over a longer horizon, the economy is expected to reach the size of $1.1 trillion by 2046-47," said the report titled "Bihar: A $1-trillion Economy," released at the 4th CII East India Summit here.
According to the report, Bihar is emerging as a unique opportunity for investors buoyed by rapid economic transformation, demographic advantage, and policy-driven dynamism.
The state is one of the fastest-growing states in the country.
In 2023-24, Bihar recorded a GSDP of Rs 8.54 lakh crore, growing at 14.4 per cent at current prices, surpassing India's growth rate of 12 per cent for the corresponding year, it said.
This surge is the result of sustained structural improvements underpinned by policy reforms, expanding infrastructure and a deliberate pivot towards industrial growth.
Traditionally known for its rich agricultural base, Bihar is now strategically shifting its focus towards agro-based industries, IT and IT-enabled services (ITES), textiles and leather sectors, manufacturing and healthcare among others, the report stated.
In 2016, the state launched the Bihar Industrial Investment Promotion Policy for promoting industrial development in the region. The policy was further amended in 2020 and extended till 2025 to make it more investor-friendly, CII said in the report.
The policy offers a wide range of incentives, including capital subsidies, power and rental rebates employment generation and skill training grants, SGST reimbursements and land subsidies.
Besides, the state government has also been very proactive in terms of notifying policies for other emerging industries such as biofuel, logistics, startups, IT, tourism and exports among others, as per the report.
In addition, the single-window system, digital land records, and pro-business reforms are enhancing the ease of doing business, while the Startup Bihar initiative is nurturing grassroots innovation, CII said in its report.
Stating that Bihar's economy has several comparative advantages that underpin the target of $1 trillion by 2047, the report said, adding that the state is blessed with abundant natural resources, including fertile land, minerals, and water.
These resources offer immense potential for various industries, such as agriculture, food processing, and manufacturing, it said.
Moreover, the majority of the state remains a rural economy with a 12 per cent urbanisation compared to 35 per cent at the all-India level. This presents a huge economic opportunity for the state to plug in, it said, adding that this also would mean a growing consumer market.
Also with nearly 58 per cent of the state's 12.7 crore residents under the age of 25, it has the youngest population among Indian states. This creates a vast, trainable, and cost-elective workforce -- critical for industries, the report added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
NSUI first to release manifesto, promises e-bike stations and mental health counselling
Chandigarh: Solar rooftops, subsidised canteens, 24×7 health centres, ramps and lifts, even e-scooter stations- NSUI opened the manifesto season at Panjab University with a catalogue of promises that sounded ambitious, but to many on campus, familiar. Tired of too many ads? go ad free now Last year's commitments of placements, self-defence classes and pad-vending machines still remain unfulfilled, and doubts are already circling whether this manifesto will fare any better. The Congress-backed student body released its document at Chandigarh Congress office, with NSUI national president Varun Choudhary and Chandigarh Congress chief H S Lucky present. Choudhary said the manifesto "reflected the aspirations of every student" and would help NSUI "sweep the elections." Asked how the long list would be assured, Lucky replied, "Manifesto means manifestation, and the motive is to strive for it. " The manifesto covers nearly every aspect of campus life: OBC reservation in admissions and hostels, scholarships for EWS students, a "One PU, One App" for grievances and results, 24×7 innovation hubs in unused classrooms, subsidised food with daily menu voting, women's safety desks, leadership programmes, sports scholarships, and more. Yet PU's lived reality points to a wide gap. As reported earlier this week, manifestos at PU "promise the moon but deliver not even an email ID." On disability access, NSUI talks of ramps and lifts. But even after a Punjab State Human Rights Commission directive and memorandums by students from 2023, PU still lacks a basic ramp at the SBI fee counter where every student queues, as reported in June. An accessibility audit in 2024 exposed further deficits, while last year's council chose to prioritise cultural fests instead. Tired of too many ads? go ad free now Women's safety is another major plank. NSUI promises a 24×7 task force, grievance desks and full CCTV coverage. But PU already struggles with inadequate security staff, and despite budget approval in December for CCTV expansion, installation is yet to begin. As TOI reported in July, even with the library buzzing 24×7, many women students avoid the dark, poorly lit roads leading back to their hostels. Mental health counselling, too, finds mention. But counselling is already mandatory under UGC norms, and PU has only one part-time counsellor for over 16,000 students- a crisis TOI exposed in July. Likewise, the pledge for a YouTube channel ignores that PU already runs one. With the university facing a financial crunch and still awaiting over Rs 47 crore for hostel construction, proposals like solar rooftops, e-scooter stations and 24×7 doctors sound more like slogans than plans. The much-touted "One PU, One App", pitched as a digital hub for results, grievances, library and transport- also seems a distant dream. PU councils have failed for years to provide students even a basic official email ID, despite repeated assurances in manifestos. Against that backdrop, an all-in-one app looks more like a distant hope than a deliverable. Choudhary admitted NSUI could only "pressurise" the administration, without explaining how the projects would move from manifesto to implementation. Still, by releasing its manifesto first, NSUI has forced other groups to catch up. Whether this document turns into delivery or another year of recycled paper promises is the question weighing on PU voters.
Economic Times
an hour ago
- Economic Times
Stock Radar: Bajaj Auto showing signs of reversal after falling over 30% from highs; medium term should ‘buy the dip'
Bajaj Auto Ltd, part of the automobile space, bounced back after taking support below the 100-DMA on the daily charts and is gradually moving traders with a high risk profile can look to buy the stock for a possible target of Rs 9,700 in the next 2-4 months, suggest 2-3-wheeler stock hit a high of Rs 12,772 on September 27, 2024, but it failed to hold the momentum. It closed at Rs 8,588 on August 18, 2025 which
Economic Times
an hour ago
- Economic Times
Aurobindo Pharma closing in on $5.5b Zentiva buyout
Boost to Aurobindo's European footprint Live Events Change of hands (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Mumbai: Aurobindo Pharma has emerged as the frontrunner to acquire Prague-based generic drugmaker Zentiva for $5-5.5 billion (Rs 43,500-47,900 crore) from Advent International , said several people aware of the matter, underscoring the growing consolidation of pharmaceutical assets in successful, this will be the largest-ever acquisition by an Indian pharma company, both at home and abroad, trumping the $3.2-billion acquisition of Daiichi Sankyo's stake in Ranbaxy in 2014, or Biocon Biologics' $3.3 billion cash and stock buyout of the global biosimilars business of US-based is competing with US private equity firm GTCR , the other serious contender left in the fray. Both sides are engaged in intense negotiations to finalise the various commercial and operations aspects of the late last year, Advent has been engaged with advisers Goldman Sachs and boutique investment bank PJT Partners to explore exit options for Zentiva, which it acquired seven years were made to several financial investors, including TPG and pharma competitors worldwide for a potential takeover.'The competition heated up from May. The binding offers have been submitted a few weeks ago and ongoing discussions have reached an advanced stage,' said a PE executive involved in the matter. 'Price is no longer being negotiated… A formal announcement can happen in the next fortnight or a month.'Zentiva will significantly boost Aurobindo's European footprint, specifically in the east European region–Czech Republic, Romania and Slovakia—where the market is seen as fertile and steadily warming up to a raft of biosimilars, following patent expiries of big prescription brands. Besides, as most healthcare spending in eastern Europe is led by government bulk public procurement, the returns are steadier as compared to perpetual price erosion in the revenues from Europe are already the highest among all other homegrown pharma peers. For calendar 2024, Zentiva Group's revenues were 1.7 billion euros ($1.98 billion) at an ebitda of 400 million euros ($467 million). Even then, analysts are surprised at the boldness of the bet that the Hyderabad-based company is willing to take amid heightened geopolitical risks and tariff market value stands at Rs 63,684.90 crore ($7.4 billion), whereas Zentiva is privately held. According to people aware of developments, Aurobindo has already secured a $4.75-billion credit line from MUFG–the sole financier in the transaction–as a bridge loan for the transaction. The remaining $800 million will be from the company's internal and Zentiva didn't respond to queries. Advent and MUFG declined to was the first to report on the Zentiva sale last November and on Aurobindo's interest in July this origins that can be traced back to Black Eagle Pharmacy from the 15th century, Zentiva was nationalised in 1946 and has undergone several ownership changes, including one in 1998 when the management team had taken over a majority share to refocus on branded generics. A decade later, in 2009, it got acquired by Sanofi and in 2018, got carved out by Advent for $2.4 billion, a deal process that had even seen a preliminary interest from India's Torrent the years, it has diversified its presence across categories such as prescription drugs, OTC products and consumer health and food supplements as well as geographies, growing both organically and through a series of buyouts across the region. It currently operates in 30 countries and has set a goal to reach one in five people across Europe by India, Zentiva has a manufacturing site in Gujarat. In 2022, Polish firm Pol Pharma, backed by a few private equity players, was reported to have placed a $3.5-billion bid for Zentiva, but the discussions remained inconclusive as the owners were reportedly considering a public leading drugmakers such as Biocon and, more recently, Lupin, have struck separate deals with Zentiva to push their biosimilars in the European region. Aurobindo is developing a robust pipeline of biosimilars such as denosumab (Prolia) for osteoporosis as well as omalizumab (Xolair) and bevacizumab (Avastin) for multiple cancer treatments.'While pricing pressure persists in chronic therapies, the European Union (EU) remains attractive for oncology and retail segments. Ongoing investments in EU-focused capacity continue to support volume growth,' said Amey Chalke of JM EU business of Aurobindo reported 9% revenue growth in the June quarter, from a year ago, with a strong performance across major markets and is on track to cross 1 billion euros in annual revenue in FY26. Injectables grew about 20% from the year earlier, driven by shortage-led demand. Two new oncology lines are being added to meet rising needs, as per the company also received four biosimilar approvals with commercial supplies initiated in the UK and full ramp-up expected in the third or fourth quarter of this fiscal. Aurobindo is targeting 40–60% margins in the EU biosimilar segment and aims for a blended 50% gross margin. Inhouse manufacturing now exceeds half the total formulations volumes, thereby boosting margins, inching toward 20% Aurobindo's FY25 consolidated sales of Rs 31,724 crore ($3.6 billion), the US market accounted for Rs 14,186 crore, up 6.8% from the year earlier. The European business grew 16.6% to Rs 8,356 month, Aurobindo acquired US-based contract development and manufacturing organization (CDMO) player Lannett for $250 million to shore up its manufacturing presence in the US while enhancing its capabilities in manufacturing complex generic drugs such as controlled at least three previous occasions, Aurobindo has either lost out to rivals or had to back out of marque transactions after announcing them. In 2020, it had to call off its deal to acquire the oral solids and dermatology business of Sandoz (part of Novartis) in the US for $900 million, failing to receive due approvals from US Federal Trade Commission even after two years.
